Coherus BioSciences (NASDAQ:CHRS) Full Year 2024 Results

Key Financial Results

• Revenue: US$267.0m (up 3.8% from FY 2023).
• Net income: US$28.5m (up from US$237.9m loss in FY 2023).
• Profit margin: 11% (up from net loss in FY 2023).
• EPS: US$0.25 (up from US$2.53 loss in FY 2023).

CHRS Post-Clinical Trial Products

• Launched (during full year): 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Coherus BioSciences Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 4.5%. Earnings per share (EPS) also surpassed analyst estimates by 31%.

In the last 12 months, the only revenue segment was Developing and Commercializing Biosimilar Products contributing US$267.0m. The largest operating expense was General & Administrative costs, amounting to US$161.1m (63% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$133.5m. Explore how CHRS's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 20% growth forecast for the Biotechs industry in the US.

The company's shares are up 1.9% from a week ago.

Risk Analysis

You should always think about risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.